Spinal muscular atrophy

Alpha Cognition Announces First Quarter 2022 Results and Company Update

Retrieved on: 
Tuesday, May 31, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, P-value, Memantine, Company, Disease, R, G&A, Research, Depreciation, Growth hacking, Amyotrophic lateral sclerosis, News, Transaction, File, Dementia, Advertising, Traumatic brain injury, OTC Markets Group, Concussion, USD, COVID-19, Failure, TSX, FDA, Neurodegeneration, Alzheimer's disease, Industry, Cognition, Spinal muscular atrophy, Terminology, Central nervous system, Safety, Technology, Donepezil, TSX Venture Exchange, NDA, ACOG, Acquisition, Rivastigmine, Growth, Patient safety, ALS, Pharmaceutical industry, Dietary supplement, Cryptocurrency

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2022.
  • "Alpha Cognition reported positive preclinical data with ALPHA-1062 intranasal for mTBI and ALPHA-0602 for ALS during the first quarter of 2022 and continued to build-out our experienced leadership team.
  • The Company also plans to meet with the FDA for the ALPHA-1062 intranasal for mTBI during the third quarter of 2022.
  • During the second quarter of 2022, the company met with FDA regarding the ALPHA-1062 program for mild-to-moderate Alzheimers Disease.

Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease

Retrieved on: 
Tuesday, May 31, 2022
U.S. Securities and Exchange Commission, BIIB, YouTube, Private Securities Litigation Reform Act, Twitter, SEC, Social media, Toxic shock syndrome, Disease, Neurodegeneration, LRRK2, Biology, Therapy, COVID-19, Failure, Nobel Prize, Research, Climate, III, Multiple sclerosis, Biomarker, Pathology, GLOBE, Traffic barrier, Science, LUMA, Health, Trial of the century, Confirmation, Biotechnology, LinkedIn, Neuroscience, Security (finance), Senior, Risk, Parkinson's disease, Patient, NASDAQ, Lists of diseases, Form 10-K, BBB, Intellectual property, Spinal muscular atrophy, Forward-looking statement, Safety, Regulatory science, Drug development, Mutation, ATV, Pharmaceutical industry, Facebook, Biogen

Initiation of the LUMA study marks an important milestone in the development of BIIB122 as a potentially first-in-class oral LRRK2 therapy for Parkinsons disease.

Key Points: 
  • Initiation of the LUMA study marks an important milestone in the development of BIIB122 as a potentially first-in-class oral LRRK2 therapy for Parkinsons disease.
  • Denali and Biogen are co-developing and co-commercializing BIIB122 for the potential treatment of Parkinsons disease.
  • The BIIB122 clinical development program includes both the LUMA Phase 2b study and the Phase 3 LIGHTHOUSE study in individuals with Parkinsons disease with LRRK2 pathogenic variants.
  • Together, Biogen and Denali have designed a rigorous development program to evaluate BIIB122 in patients with and without LRRK2 mutations.

AskBio President of Therapeutics Dr. Katherine High receives Award from American Society of Gene and Cell Therapy

Retrieved on: 
Monday, May 23, 2022
NAS, Physician, Muscular dystrophy, Patent, Parkinson's disease, Hospital, Capsid, Food, National, Multimedia, Patient, Goal, Spark Therapeutics, Association, Therapy, Clinical trial, Society, Bayer, National academy, COVID-19, RESEARCH, Spinal muscular atrophy, Trust, Feedback, Secondary research, Research, Gene, FDA, Glycogen storage disease type II, PARK, Food and Drug Administration, Heart, Disagreement, CHOP, AAV, Lists of diseases, Center, Kaay Raav Tumhi, Pompe, Human, Central nervous system, Technology, Inauguration, Research Triangle Park, Child, United States Patent and Trademark Office, Ageing, Voretigene neparvovec, Group, American Society of Gene and Cell Therapy, LinkedIn, Person, Cell, Growth, Mendell, MD, Medical device, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C.  , May 23, 2022 /PRNewswire/ --  Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced that Dr. Katherine High, President of Therapeutics, received the Jerry Mendell award for Translational Science from the American Society of Gene and Cell Therapy (ASGCT).  Recently inducted as a member of the National Academy of Sciences (NAS), Dr. High has received this award in recognition of her significant contributions to the field of genetic medicine.

Key Points: 
  • Today, at AskBio, Dr. High oversees a robust pipeline of gene therapeutics to treat various neuromuscular, central nervous system, cardiovascular and metabolic disorders, all at various stages of clinical development.
  • Today, the ASGCT is the largest association of individuals involved in gene and cell therapy research.
  • AskBio's gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive capsid and promoter library.
  • AskBio does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Eastern & Western PA Harley-Davidson Dealers Associations Raise Over $900,000 for MDA at 35th Annual Ride For Life

Retrieved on: 
Tuesday, May 17, 2022
SMA, Muscular Dystrophy Association, Muscular dystrophy, MDA, Neuromuscular disease, Multimedia, View, Association, Degenerative disease, Research, Weather, Ice cream, Partnership, TikTok, Spinal muscular atrophy, Program, Lock, Lean, LinkedIn, Twitter, Life, ALS, Harley-Davidson, Entertainment, Facebook, Instagram

NEW YORK, May 17, 2022 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) today announced the Eastern Harley-Davidson Dealers Association with the Western PA Harley-Davidson Dealer Association 35th Annual MDA Ride for Life in Lebanon, PA raised $914,140 in support of research, care, and advocacy for people living with neuromuscular disease.

Key Points: 
  • NEW YORK, May 17, 2022 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) today announced the Eastern Harley-Davidson Dealers Association with the Western PA Harley-Davidson Dealer Association 35th Annual MDA Ride for Life in Lebanon, PA raised $914,140 in support of research, care, and advocacy for people living with neuromuscular disease.
  • chapters raising money and making the trek to Ride for a Reason Ride for Life for MDA families!"
  • "13 MDA families attended throughout the weekend, and ambassadors got to ride in their favorite sidecars again!"
  • We are so grateful to Harley-Davidson Eastern and Western Pennsylvania Dealers, an incredibly generous group of people."

Biophytis: Biophytis announces its participation at the BIO International Convention in San Diego from the 13th to the 16th of June

Retrieved on: 
Thursday, May 12, 2022
SMA, Business, U.S. Securities and Exchange Commission, Company, Patient, AMF, Business development, Phase II, Review, Private law, DMD, SARA, COVID-19, Degenerative disease, Trial of the century, ADS, BIO, AMD, MACA, Biotechnology, Forward-looking statement, Biotechnology Innovation Organization, Ecosystem, Ageing, CET, Therapy, Spinal muscular atrophy, Euronext Growth, SEC, American depositary receipt, Duchenne muscular dystrophy, Security (finance), Ticker, CEO, Pharmaceutical industry, Nasdaq, Sarcopenia

Biophytis' participation in BIO is aligned with the Company's strategy to partner with global or regional players to license and co-develop its core assets.

Key Points: 
  • Biophytis' participation in BIO is aligned with the Company's strategy to partner with global or regional players to license and co-develop its core assets.
  • In addition to these projects in age-related diseases, Biophytis has built a portfolio of assets in rare neuromuscular diseases targeting Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA).
  • This MYODA clinical study could start late 2022 or early 2023, depending on the evolution of the pandemic.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis.

Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis

Retrieved on: 
Thursday, May 5, 2022
Hope, COVID-19, Stroke, Neuroscience, Private Securities Litigation Reform Act, YouTube, Music, Twitter, Nasdaq, U.S. Securities and Exchange Commission, Failure, GLOBE, Nobel Prize, Multiple sclerosis, Biotechnology, Spinal muscular atrophy, MS, Software, Gait, Patient, Risk, RAS, Lists of diseases, BIIB, Therapy, Neurology, Health, Quality of life, Movement, LinkedIn, Science, Climate, Intellectual property, News, Technology, Area studies, Walking, Pathology, Social media, Pharmaceutical industry, Risk management, Biogen, Facebook

The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)

Key Points: 
  • The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
    CAMBRIDGE, Mass.
  • and PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and MedRhythms have entered into a license agreement to develop and commercialize MR-004, an investigational prescription digital therapeutic for the potential treatment of gait deficits in multiple sclerosis (MS).
  • The collaboration combines MedRhythms digital expertise with Biogens leadership and global footprint in MS in order to address significant unmet patient needs.
  • Under the terms of the agreement, Biogen will make an upfront payment of $3 million to MedRhythms.

Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis

Retrieved on: 
Thursday, May 5, 2022
Technology, Research, Entertainment, Software, Biotechnology, Health, Music, Pharmaceutical, Science, Hope, COVID-19, Stroke, Neuroscience, Private Securities Litigation Reform Act, YouTube, Music, Twitter, Nasdaq, U.S. Securities and Exchange Commission, Failure, Inc., Nobel Prize, Multiple sclerosis, Biotechnology, Spinal muscular atrophy, MS, Software, Gait, Patient, Risk, Lists of diseases, BIIB, Therapy, Multimedia, Neurology, Health, Quality of life, Movement, LinkedIn, Science, Climate, Intellectual property, News, Technology, Area studies, Walking, Pathology, Social media, Pharmaceutical industry, Risk management, Biogen, Facebook

Biogen Inc. (Nasdaq: BIIB) and MedRhythms have entered into a license agreement to develop and commercialize MR-004, an investigational prescription digital therapeutic for the potential treatment of gait deficits in multiple sclerosis (MS).

Key Points: 
  • Biogen Inc. (Nasdaq: BIIB) and MedRhythms have entered into a license agreement to develop and commercialize MR-004, an investigational prescription digital therapeutic for the potential treatment of gait deficits in multiple sclerosis (MS).
  • The collaboration combines MedRhythms digital expertise with Biogens leadership and global footprint in MS in order to address significant unmet patient needs.
  • MR-004 is MedRhythms pipeline candidate in MS, which aims to improve gait and gait-related aspects of movement, potentially providing MS patients with improved independence related to mobility.
  • Under the terms of the agreement, Biogen will make an upfront payment of $3 million to MedRhythms.

Sumo Logic Appoints John D. Harkey, Jr. to Board of Directors

Retrieved on: 
Tuesday, May 3, 2022
Transfer, Acadia Pharmaceuticals, Love, Compensation, Founder, State Fair, Board of directors, SEC, Circle Ten Council, CEO, Entrepreneurship, Forward-looking statement, Leap Wireless, Director, Company, Novartis Gene Therapies, Energy, Communication, State Fair of Texas, Loral Space & Communications, Heroin, Dallas Arboretum and Botanical Garden, Spinal muscular atrophy, Software as a service, Therapy, Energy Transfer Partners, Investment, Nicotine, Fentanyl, Telesat, Boy Scouts, Vaccine, AT, Logic, Growth, Board, Novartis, Novo Nordisk, Nasdaq, GLOBE, LLC, Telecommunication, MD Anderson Cancer Center, Restaurant, Sumo Logic, Management, Security (finance)

With this addition, the Sumo Logic Board will consist of ten directors, eight of whom are independent.

Key Points: 
  • With this addition, the Sumo Logic Board will consist of ten directors, eight of whom are independent.
  • Additionally, Sumo Logic has agreed with Scalar Gauge to collaborate on an ongoing process aimed at identifying and appointing an additional director.
  • We are looking forward to working with John, said Ramin Sayar, President and CEO of Sumo Logic.
  • Sumo Logic has strong momentum with accelerating revenue growth backed by a refreshed and best in class go-to-market strategy.

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress

Retrieved on: 
Thursday, April 21, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, EMA, RPD, File, U.S. Securities and Exchange Commission, COVID-19, Pathology, Security (finance), NASDAQ, Muscle weakness, Risk, Patient, LinkedIn, Neuromuscular Disorders, Review, European Medicines Agency, Ground Floor, Hammersmith, FDA, Securities Act of 1933, Myostatin, Food, Human, Private Securities Litigation Reform Act, Motor neuron, SMA, Social media, Company, Gene, Orphan drug, Congress, SMN1, Twitter, Spinal muscular atrophy, Investor, Genetic disorder, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Drug Quality and Security Act, Intellectual property, Growth, SEC, Safety, Gongshi, Fast Track, Therapy, Cancer, Survival, ODD, FTD, Fibrosis, Rock, Clinical trial, EPNS, TOPAZ, Atrophy, FAQ, SMN2, SMN, Pharmaceutical industry

Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA.

Key Points: 
  • Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA.
  • The efficacy and safety of apitegromab have not been established and apitegromab has not been approved for any use by the FDA or any other regulatory agency.
  • Spinal muscular atrophy (SMA) is a rare, and often fatal, genetic disorder that typically manifests in young children.
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.

Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis Awarded Nearly $1.35 Million to Investigate the Impact of Pediatric-Onset MS Into Adulthood

Retrieved on: 
Wednesday, April 6, 2022
Cognition, Â, Disability, Unity Health Toronto, Culture, Health care, Research, Biotechnology, Pathology, Medical director, CEO, University of Toronto, Nobel Prize, Twitter, Data, GLOBE, University, Disease, Diagnosis, Mental health, Central nervous system, Government House (Alberta), Health, Degenerative disease, Roche, Innovation, Quality of life, Hope, Brain, Multiple sclerosis, Lists of diseases, Growth, Neuroscience, Ophthalmology, Multiple Sclerosis Society, Medication, MS, Instagram, Patient, Partnership, Leadership, Spinal muscular atrophy, Government, Physical disability, ST, Inclusion, Multiple Sclerosis Society of Canada, Foundation, Spinal cord injury, Infection, Pharmaceutical industry, Oil, Medicine, Medical device, Drug, Medical imaging, Creative industries, Biogen, Woman, Facebook

This investment over three years brings the total amount awarded for the CanProCo project to over $11.5 million.

Key Points: 
  • This investment over three years brings the total amount awarded for the CanProCo project to over $11.5 million.
  • CanProCo is generously funded by the MS Society of Canada in partnership with Brain Canada Foundation, Biogen Canada, Roche Canada, and the Government of Alberta.
  • To learn more about the new sub-cohort of the Canadian Prospective Cohort Study to Understand Progression in MS, visit our funded research page .
  • Progression or the steady worsening of disease, resulting in increased disability is a challenging reality faced by people affected by MS.